Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials.

Abstract

AIMS:

To study the short-term cardiovascular effects of the once-weekly glucagon-like peptide-1 receptor agonist taspoglutide.

METHODS:

We conducted a meta-analysis of individual-participant data from nine randomized controlled trials in the T-Emerge programme, which assessed the efficacy and safety of taspoglutide in type 2 diabetes. Our primary outcome was a composite of death from cardiovascular disease (CVD) and acute myocardial infarction, stroke and hospitalization for unstable angina.

RESULTS:

Overall, 7056 individuals were included in the analysis, and there were 67 primary endpoint events during 7478 person-years of follow-up (40 vs 27 events in the intervention vs control groups, respectively). The odds ratio for the composite endpoint among people randomized to taspoglutide was 0.94 (95% confidence interval 0.57-1.56), which was robust across multiple subgroups. Longer-term data were not available as the development of taspoglutide was stopped because of gastrointestinal intolerance and serious hypersensitivity reactions.

CONCLUSIONS:

The available data suggest that short-term, once-weekly administration of taspoglutide was not associated with an excess risk of CVD, and provide insights relevant to the development of other novel once-weekly incretin mimetics.

• Authors: S R K Seshasai, R L Bennett, J R Petrie, M Bengus, S Ekman, M Dixon, M Herz, J B Buse, K K Ray
• Journal: Diabetes, obesity & metabolism (Diabetes Obes Metab) Vol. 17 Issue 5 Pg. 505-10 (May 2015) ISSN: 1463-1326 [Electronic] England
• PMID: 25656522 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review)
• Copyright: © 2015 John Wiley & Sons Ltd.

Chemical References

• Glucagon-Like Peptide-1 Receptor
• Peptides
• taspoglutide

Topics

• Cardiovascular Diseases (etiology)
• Clinical Trials, Phase III as Topic
• Diabetes Mellitus, Type 2 (drug therapy)
• Drug Administration Schedule
• Female
• Glucagon-Like Peptide-1 Receptor (administration & dosage, agonists)
• Humans
• Male
• Middle Aged
• Peptides (administration & dosage, adverse effects)
• Randomized Controlled Trials as Topic
• Treatment Outcome